Mani Subramanian, MD, PhD
Founder and CEO
Manoj Desai, PhD
Co-founder, Scientific Advisor
Steve Weng, MBA
Vice President, Product Development and Program Management
Gautham Pranesh, MD
Assay Development & Non-Clinical Studies
MitoPower LLC. is an early stage biopharmaceutical company that is focused on diseases associated with severe mitochondrial dysfunction. Our lead candidate MP-04 is a small molecule compound that is being developed for the treatment of patients with end stage liver disease.
MitoPower is developing MP-04, a small molecule that enhances mitochondrial function. MP-04 has shown promising results in improving cellular metabolism and reversing organ dysfunction in pre-clinical studies. MP-04 will initially be indicated for the treatment of patients with liver failure, including acute on chronic liver failure (ACLF).